A Study Comparing a Shorter Exposure of Oocyte to Spermatozoa Versus a Standard Incubation on the Live Birth Rate of In-vitro Fertilization Treatment
NCT ID: NCT02534857
Last Updated: 2015-08-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
280 participants
INTERVENTIONAL
2015-09-30
2017-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A recent meta-analysis shows brief incubation of gametes was associated with significantly higher rates of clinical pregnancy , ongoing pregnancy and higher rate of implantation than standard incubation. But the rates of normal fertilization, good quality embryos and polyspermy were not significantly different compared with standard incubation. In a Cochrane meta-analysis, eight RCTs with 733 women were included, and showed similar results. But it only reported clinical pregnancy rate and ongoing pregnancy rate which were significantly higher in brief incubation group than standard incubation. However, the live birth rate, which is the important outcome parameter, was not reported in all these studies. It is uncertain whether brief incubation improves the life birth rate compared with standard incubation.
The aim of this randomized double blinded study is to compare the live birth rate of IVF treatment following brief incubation of oocytes and sperm versus standard incubation. The hypothesis is that a brief incubation improves the live birth rate of IVF treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Follicular Flushing in Patients With Suboptimal Responses
NCT02277210
Comparison of the Number of Oocytes Obtained Between Chinese and Caucasian Women in IVF Treatment
NCT02748278
Co-incubation of Oocytes With Sperm: Defining the Optimal Incubation Time
NCT04627545
Injection of Day 2 Embryo Culture Supernatant Into the Uterine Cavity Didn't Improve Implantation and Pregnancy Rates
NCT00730496
The Effect of Covid-19 Vaccination in Patients Undergoing IVF
NCT05063942
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In vitro fertilization (IVF) technique is now commonly used for the treatment of infertile couples. To obtain better outcomes of IVF, it is important to enhance embryo quality by optimizing IVF techniques. In IVF procedures, oocytes and sperm are routinely co-incubated overnight, which may expose oocytes and zygotes to suboptimal culture conditions with increased reactive oxygen species (ROS) produced by sperm in this long term culture\[1\]. High levels of reactive oxygen species (ROS) can adversely affect the quality of the embryos, result in hardening of the zona pellucida and impair the implantation capacity of embryos \[2-4\]. Studies shows successful fertilization of a mamamal oocyte occurs 20mins after gametes meet \[5\]. Sperm can penetrate through the cumulus cells within 15min, and 80% of oocytes can be fertilized when they are exposed to a large number of spermatozoa within 1hrs\[1\]. As an attempt to avoid possible detrimental effects on the oocytes from long exposure to sperm, the brief co-incubation insemination protocol was developed. It implies that long-term co-incubation of oocytes and sperm may not be necessary and may even be harmful. Some reports suggest that a sperm-oocyte exposure time of 1-6 h improves IVF outcomes\[1,2,6,7\] However, other studies report no such advantage with a short insemination time\[8,9,10\] .
Recent published Meta analysis shows\[11\] brief co-incubation of gametes was associated with significantly higher rates of clinical pregnancy (RR: 1.84, 95% CI: 1.24-2.73), ongoing pregnancy (RR: 1.73, 95%CI: 1.27-2.33) and higher rate of implantation (RR: 1.80, 95% CI: 1.43-2.26) than standard insemination. But the rates of normal fertilization (RR: 0.98, 95% CI: 0.93-1.02), good quality embryos (RR: 1.24, 95% CI: 1.0-1.53) and polyspermy (RR: 0.84, 95% CI: 0.7-1.01) were not significantly different compared with standard insemination. In another Cochrane meta-analysis\[12\] eight RCTs with 733 women were included, and got the similar results. But it only reported clinical pregnancy rate, ongoing pregnancy rate which was significantly higher in brief co-incubation group than standard insemination. For the miscarriage rate, there were six miscarriages in one trial including 167 women. This low quality evidence suggested no significant difference in the odds of miscarriage between brief co-incubation and standard insemination (OR 1.98, 95% CI 0.35 to 11.09; P = 0.44). And live birth was not reported in the included studies, it is unclear whether brief co-incubation improves the life birth rate compared with the standard overnight insemination protocol.
Drawbacks inherent to the quality of these studies, such as lack of allocation concealment and no blinding, limit the quality of the available evidence. To better evaluate these issues, more well designed RCTs are required to assess whether brief co-incubation would contribute to a higher live birth rate and a lower miscarriage rate compared to the standard overnight insemination protocol.
2. Objectives:
The objective of the present randomized, double blinded controlled study is to compare clinical effectiveness (especially on live birth rate) of a shorter exposure of oocyte to spermatozoa compared to a standard incubation in women undergoing IVF treatment.
3. Trial design:
A total of 280 infertile women undergoing IVF treatment will be randomized into one of the following two groups by computer-generated random numbers that was placed in sealed envelopes:
Shorter exposure of oocyte to spermatozoa group: oocytes will be exposed to spermatozoa for 2 hours Standard incubation group: oocytes will be exposed to spermatozoa for 20 hours
Treatment of subjects
All techniques of IVF including ovarian stimulation will be according to local protocols.
4.1 Ovarian stimulation and IVF
All women started their IVF treatment with ovarian stimulation using either the long agonist or antagonist protocols. For long protocol, gonadotropin-releasing hormone analogue (GnRHa) will be given for pituitary desensitization, on Day 2-3 of the menstrual cycle, they will undergo transvaginal ultrasound examination and serum E2 measurement. Human menopausal gonadotrophin (hMG) or recombinant FSH will started at 150-300 IU per day based on the antral follicle count, age of women and previous ovarian response, according to the standard operation procedures of the centre. Ovarian response was monitored by serial transvaginal scanning with or without hormonal monitoring. Further dosage adjustments will base on the ovarian response at the discretion of the clinicians in charge. For antagonist protocols, antagonist (cetritide0.25mg daily) will be given on the 6th day of ovarian stimulation until day of hcg priming.
When three leading follicles were ≥18 mm, hCG 10 000 IU or ovidrel 250 mg will be given to trigger final maturation of oocytes. Oocyte retrievals will be arranged around 36 h later.
4.2 Insemination Procedures
All semen samples were prepared by the conventional swim-up procedure. At2hr after oocyte retrieval, each matured oocyte will be inseminated with approximately 50,000-100,000 motile spermatozoa.
4.3. Assignment and masking
On the day of OPU, patients will be randomized after occyte pick up by a laboratory technician according to a computer generated randomization list in sealed envelopes into the shorter incubation group or the control group. Until the completion of the whole study, both the patients and the clinicians were blinded to the group assigned.
Control arm Women who allocated to the control arm, all the oocytes will be exposed to spermatozoa for 20 hours, and checked for fertilization on day 1 (20 hours) after denuding
Intervention arm For those allocated to the intervention arm, all the oocytes will be exposed to spermatozoa for 2 hours and gently wash through two organ dishes containing 1.5 ml of equilibrated medium, and then transferred to the corresponding microdroplet of equilibrated fresh medium. Surrounding cumulus cell will be retained, not removed from the ooctyes.
4.4 Fertilization and Embryo Evaluation Both groups of oocytes will be decoronated and checked for the presence of two pronuclei and two polar bodies to confirm fertilization. All other outcomes (i.e., no fertilization, one pronucleus, polyspermia, degeneration) were also recorded.
Embryo morphology will be assessed every day of culture. Embryos will be scored according to the following criteria. Briefly, embryos are classified as: gradeA, no cellular fragmentation; grade B, \<20% fragmentation; grade C, 20% to 50% fragmentation; and grade D, \>50% fragmentation. The number of blastomeres per embryo was also recorded. Grade A and B embryos constituted the "good quality embryo".
The transfer is performed by the team clinician with a maximum of 2 embryos being replaced according to the standard protocol under transabdominal ultrasound guidance. Luteal phase support is given at the discretion of the physician.
4.5 Follow up strategy:
A pregnancy test will be carried out 2 weeks after embryo transfer in both arms. All women who have a positive pregnancy test 2 weeks after a fresh embryo transfer will undergo a transvaginal ultrasound scan after a further 5 weeks to identify the presence of a gestation sac with a fetal heart signifying an ongoing pregnancy.
Data on all pregnancy outcomes including early pregnancy losses such as miscarriage or ectopic pregnancy will be collected.
In order to achieve consistency with respect to the collection of outcome, standardised case report forms (CRF) will be completed for each woman at each centre. These CRFs will include details on treatment received, pregnancy outcomes, complications in pregnancy, mode of delivery and birth outcomes.
Statistics
5.1 Analysis plan: Demographic factors and clinical characteristics collected as part of baseline data collection will be summarised with counts (percentages) for categorical variables, mean (standard deviation \[SD\]) for normally distributed continuous variables, or median (interquartile \[IQR\] or entire range) for other continuous variables.
Outcomes for participants will be analysed in the groups to which they are assigned regardless of deviation from the protocol or treatment received (intention-to-treat). Comparative statistical analysis will entail calculating the relative risk (RR) (95% CI) for the primary outcome (99% CIs for all dichotomous secondary outcomes), the mean difference (99% CI) for normally distributed continuous secondary outcomes, or the median difference (99% CI) for skewed continuous variables.
All analyses will adjust for the minimisation factors to account for the correlation between treatment groups introduced by balancing the randomisation (which forces outcomes between treatment arms to be similar apart from any treatment effect).
Adjusted risk ratios will be estimated using a log binomial regression model, or using a log Poisson regression model with a robust variance estimator if the binomial model fails to converge. Linear regression will be used for normally distributed outcomes and quantile regression for skewed continuous variables.
Pre-specified subgroup analyses will include Cleavage versus blastocyst stage transfer.
6\. Sample size estimation:
The average live birth rate in our center from 2010-2012 was 30% per transfer. According to recent published Meta analysis\[11\],brief co-incubation of gametes was associated with significantly higher rates of ongoing pregnancy (RR: 1.73, 95%CI: 1.27-2.33) than standard insemination.
Assuming live birth in the treatment group =50% (increase by 70%); with 90% power and a two-sided 5% level of statistical significance, we will need to recruit 124 women in each arm. To account for 10% loss to follow up, we will recruit 140 subjects in each group or 280 subjects for the whole study.
7\. Assessment of safety
Recults from recent published Meta analysis\[11,12\] showed the rates of normal fertilization, good quality embryos and polyspermy were not significantly different with short time incubation of gametes compared with standard insemination. Thus, there should be no major safety concern in this study.
8\. Direct access to source data / documents:
Trial-related monitoring, audits, IRB review and regulatory inspections are allowed.
9\. Quality control and quality assurance
Patients will be managed by the listed investigators who have adequate experience in managing assisted reproduction treatments. A Trial steering committee will be formed which will oversee the conduct of the trial.
10\. Ethics
Written consent will be obtained from all patients. The patient information sheet and consent forms in English and Chinese are enclosed. Ethics approval will be obtained from the Institutional Review Board, Shanghai first Maternity and Infant health hospital Hospital.
11\. Data Handling and record keeping
All data will be stored for three years. A designated research nurse will be responsible for data management including data coding, monitoring and verification.
12\. Financing and insurance
The study will be funded by MerckSerono China Research Fund for Fertility Experts.
13\. Publication policy
The findings of this study will be submitted for consideration for publication in peer-reviewed scientific journal.
14\. Supplements
The study will be conducted in compliance with the Declaration of Helsinki and Good Clinical Practice (ICH-GCP)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention arm
Those allocated to the intervention arm, all the oocytes will be exposed to spermatozoa for 2 hours and gently wash through two organ dishes containing 1.5 ml of equilibrated medium, and then transferred to the corresponding microdroplet of equilibrated fresh medium. Surrounding cumulus cell will be retained, not removed from the ooctyes.
a shorter exposure of oocyte to spermatozoa
Shorter exposure of oocyte to spermatozoa group: oocytes will be exposed to spermatozoa for 2 hours
Control arm
Women who allocated to the control arm, all the oocytes will be exposed to spermatozoa for 20 hours, and checked for fertilization on day 1 (20 hours) after denuding
a shorter exposure of oocyte to spermatozoa
Shorter exposure of oocyte to spermatozoa group: oocytes will be exposed to spermatozoa for 2 hours
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
a shorter exposure of oocyte to spermatozoa
Shorter exposure of oocyte to spermatozoa group: oocytes will be exposed to spermatozoa for 2 hours
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Any indications for conventional insemination such as tubal, endometriosis, unexplained and mild male factor
* Written informed consent
Exclusion Criteria
* Women with abnormal uterine cavity shown on hysterosalpingogram or saline infusion sonogram
* Women with hydrosalpinges shown on scanning and not corrected treated
* Husband with severe oligospermia or azospermia or teraspermia (nomal morphology\<5%)
* Previous fertilization failure for conventional insemination in the past (fertilization rate\<30%)
42 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The University of Hong Kong
OTHER
Shanghai First Maternity and Infant Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
chen zhi qin
Shanghai First Maternity and Infant Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai first Maternity and Infant health hospital, Tong Ji University
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Waldenstrom U, Hamberger L, Nilsson L, Ryding M. Short-time sperm-egg exposure to prevent zona hardening. J Assist Reprod Genet 1993;10:190
Wassarman PM. Fertilization in mammals. Sci Am. 1988 Dec;259(6):78-84. doi: 10.1038/scientificamerican1288-78. No abstract available.
Gianaroli L, Fiorentino A, Magli MC, Ferraretti AP, Montanaro N. Prolonged sperm-oocyte exposure and high sperm concentration affect human embryo viability and pregnancy rate. Hum Reprod. 1996 Nov;11(11):2507-11. doi: 10.1093/oxfordjournals.humrep.a019149.
Kattera S, Chen C. Short coincubation of gametes in in vitro fertilization improves implantation and pregnancy rates: a prospective, randomized, controlled study. Fertil Steril. 2003 Oct;80(4):1017-21. doi: 10.1016/s0015-0282(03)01154-3.
Lundqvist M, Johansson U, Lundkvist O, Milton K, Westin C, Simberg N. Reducing the time of co-incubation of gametes in human in-vitro fertilization has no beneficial effects. Reprod Biomed Online. 2001;3(1):21-24. doi: 10.1016/s1472-6483(10)61959-1.
Chen C, Kattera S. Rescue ICSI of oocytes that failed to extrude the second polar body 6 h post-insemination in conventional IVF. Hum Reprod. 2003 Oct;18(10):2118-21. doi: 10.1093/humrep/deg325.
Zhang XD, Liu JX, Liu WW, Gao Y, Han W, Xiong S, Wu LH, Huang GN. Time of insemination culture and outcomes of in vitro fertilization: a systematic review and meta-analysis. Hum Reprod Update. 2013 Nov-Dec;19(6):685-95. doi: 10.1093/humupd/dmt036. Epub 2013 Aug 2.
Huang Z, Li J, Wang L, Yan J, Shi Y, Li S. Brief co-incubation of sperm and oocytes for in vitro fertilization techniques. Cochrane Database Syst Rev. 2013 Apr 30;2013(4):CD009391. doi: 10.1002/14651858.CD009391.pub2.
Gianaroli L, Cristina Magli M, Ferraretti AP, Fiorentino A, Tosti E, Panzella S, Dale B. Reducing the time of sperm-oocyte interaction in human in-vitro fertilization improves the implantation rate. Hum Reprod. 1996 Jan;11(1):166-71. doi: 10.1093/oxfordjournals.humrep.a019011.
Dirnfeld M, Bider D, Koifman M, Calderon I, Abramovici H. Shortened exposure of oocytes to spermatozoa improves in-vitro fertilization outcome: a prospective, randomized, controlled study. Hum Reprod. 1999 Oct;14(10):2562-4. doi: 10.1093/humrep/14.10.2562.
Dirnfeld M, Shiloh H, Bider D, Harari E, Koifman M, Lahav-Baratz S, Abramovici H. A prospective randomized controlled study of the effect of short coincubation of gametes during insemination on zona pellucida thickness. Gynecol Endocrinol. 2003 Oct;17(5):397-403. doi: 10.1080/09513590312331290288.
Barraud-Lange V, Sifer C, Pocate K, Ziyyat A, Martin-Pont B, Porcher R, Hugues JN, Wolf JP. Short gamete co-incubation during in vitro fertilization decreases the fertilization rate and does not improve embryo quality: a prospective auto controlled study. J Assist Reprod Genet. 2008 Jul;25(7):305-10. doi: 10.1007/s10815-008-9240-3. Epub 2008 Aug 1.
Chen ZQ, Wang Y, Ng EHY, Zhao M, Pan JP, Wu HX, Teng XM. A randomized triple blind controlled trial comparing the live birth rate of IVF following brief incubation versus standard incubation of gametes. Hum Reprod. 2019 Jan 1;34(1):100-108. doi: 10.1093/humrep/dey333.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ShanghaiFMIH
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.